Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II multicenter double-blind study of safusidenib erbumine in IDH1-mutant glioma
CTR20253759Phase 2Active
- Sponsor
- AnHeart Therapeutics
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of safusidenib in glioma, astrocytoma, Oligodendroglioma (OG), sponsored by AnHeart Therapeutics. Started Nov 2025; status: active.
02
Drugs
safusidenib
03
Conditions
gliomaastrocytomaOligodendroglioma (OG)
Beyond the preview
Go deeper on CTR20253759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253759.